Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Glioma × ivosidenib × Clear all

Phase

Status

Sponsor Class

NIH 2 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 15 Myeloproliferative Disorders 5 Myelodysplastic Syndromes 5 Cholangiocarcinoma 2 Biliary Tract Neoplasms 2 Pancreatic Ductal Adenocarcinoma 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Lymphoma, Follicular 1 Leukemia 1 IDH1 Mutation Myeloid Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Chondrosarcoma 1 AML 1

Interventions

Temozolomide 99 Magnetic Resonance Spectroscopy 46 Bevacizumab 46 Radiotherapy 41 Irinotecan 23 Blood Specimen Collection 15 Aminolevulinic Acid 15 Surgical Procedures, Operative 13 Radiation 13 Carboplatin 13 Nivolumab 12 fluorodopa F 18 10 Radiotherapy, Intensity-Modulated 10 Radiosurgery 10 Carmustine 10 pembrolizumab 9 Topotecan 9 Surveys and Questionnaires 8 Specimen Handling 8 Magnetic Resonance Imaging 8 Erlotinib Hydrochloride 8 Biopsy 8 poly ICLC 7 Standard of Care 7 Filgrastim 7 Everolimus 7 Etoposide 7 Drug Therapy 7 Cyclophosphamide 7 ribociclib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04056910 2025-02-27

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

University of Pittsburgh

Phase 2 Completed

15 enrolled 14 charts

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡